<DOC>
	<DOC>NCT01015040</DOC>
	<brief_summary>The objective of the study is to compare the relative bioavailability and pharmacokinetics of solifenacin succinate suspension versus tablet.</brief_summary>
	<brief_title>Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers</brief_title>
	<detailed_description>All subjects will participate in each treatment separated by a minimum (=&gt; minimum) of 13 days between dosing. In the two fasting periods, each subject will receive solifenacin succinate orally in each treatment period following a minimum 10 hour fast from food and beverages. In the fed condition, each subject will receive the suspension within 30 minutes of the start of breakfast.</detailed_description>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Healthy subject weighing at least 45 kg with a Body Mass Index (BMI) of 1832 kg/m2, inclusive If female, subject is at least 2 years postmenopausal, surgically sterile or practicing effective birth control and is not lactating or pregnant Medically healthy, with a normal 12lead electrocardiogram (ECG) Good venous access in both arms History of any clinically significant disease or malignancy excluding nonmelanoma skin cancer Known hypersensitivity to VESIcareÂ® or any of the excipients in the formulations, or a history of severe allergic or anaphylactic reactions History of alcoholism or substance abuse within past 2 years Has used tobaccocontaining products and nicotine or nicotine containing products within six months Supine mean systolic blood pressure &lt; 90 or &gt; 160 mmHg and a mean diastolic blood pressure &lt; 50 or &gt; 90 mmHg, or pulse rate &lt; 40 or &gt; 100 beats per minute Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg) Known positive for human immunodeficiency virus (HIV) antibody Clinical laboratory tests outside the normal limits Treatment with prescription or nonprescription drugs, including complementary and alternative medicines or overthecounter medications, with the exception of oral contraceptives, hormone replacement therapy, and occasional use of acetaminophen within 14 days prior to Day 1 Inability to abstain from alcohol or caffeine use for 48 hours prior to the administration of the first dose of study drug and throughout the duration of the study or from grapefruit, Seville oranges, star fruit, or any products containing these items from 72 hours prior to the administration of the first dose of study drug and throughout the duration of the study Donated one unit of blood or more, has had significant blood loss, or received a transfusion of any blood or blood products within 60 days or has donated plasma within 7 days prior to study checkin Any clinically significant history of gastrointestinal symptoms such as nausea, abdominal discomfort or upset, or heartburn in the four weeks prior to study checkin or a history of any gastrointestinal surgery except for appendectomy or cholecystectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>solifenacin succinate</keyword>
	<keyword>VESIcare</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>